IDH1/2 inhibitors are active in IDH1/2-mutated acute myeloid leukemia, but demonstrate limited efficacy in glioblastomas carrying IDH1/2 genetic alterations [98,99,100]. The gene discussed is IDH1; the disease is glioblastoma.